Favorable response to second-line atezolizumab and bevacizumab following progression on nivolumab in advanced hepatocellular carcinoma: A case report demonstrating that anti-VEGF therapy overcomes resistance to checkpoint inhibition

RATIONALE: Advanced hepatocellular carcinoma (HCC) remains a deadly disease in part due to decades of limited therapeutic options. With recent advances in our understanding of the tumor biology, several promising treatment strategies involving targeted and immunotherapies have emerged. However, enha...

Descripción completa

Detalles Bibliográficos
Autores principales: Swed, Brandon, Ryan, Kara, Gandarilla, Omar, Shah, Manish A., Brar, Gagandeep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238293/
https://www.ncbi.nlm.nih.gov/pubmed/34160456
http://dx.doi.org/10.1097/MD.0000000000026471

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238293/
https://www.ncbi.nlm.nih.gov/pubmed/34160456
http://dx.doi.org/10.1097/MD.0000000000026471

Ejemplares similares